

Drugs



Dermatophagoides farinae

IDENTIFICATION

Name	Dermatophagoides farinae
Accession Number	DB10400 (DB05902)
Type	Biotech
Groups	Approved
Biologic Classification	Allergenic Allergen Extract
Description	Dermatophagoides farinae extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.
Synonyms	American house dust mite American house dust mite extract House dust mite extract, dermatophagoides farinae Insects (whole body), mite dermatophagoides farinae Mite D.F. Mite D.F. (dermatophagoides farinae) standardized

Prescription Products

Show entries

NAME	DOSAGE	STRENGTH	ROUTE	LABELLER	MARKETING START	MARKETING END			
Allergenic Extract - Standardized Mite Dermatophagoides Farinae	Liquid	10000 unit	Intradermal; Subcutaneous	Greer Laboratories	1999-03-15	Not applicable			
Allergenic Extract - Standardized Mite Dermatophagoides Farinae	Liquid	5000 unit	Intradermal; Subcutaneous	Greer Laboratories	Not applicable	Not applicable			
Allergenic Extract Standardized Mite DF	Liquid	30000 unit	Subcutaneous	Hollister Stier, Unit Pharm, Division Of Miles Canada Inc.	1992-12-31	1998-09-25			
Allergenic Extract Standardized Mite DF	Liquid	10000 unit	Subcutaneous	Hollister Stier, Unit Pharm, Division Of Miles Canada Inc.	1992-12-31	1998-09-25			
Allergenic Extract Standardized Mite Df (10,000 Au/ml)	Solution	10000 unit	Percutaneous; Subcutaneous	Jubilant Hollisterstier Llc	1998-01-16	Not applicable			
Allergenic Extract Standardized Mite Df (30,000 Au/ml)	Solution	30000 unit	Percutaneous; Subcutaneous	Jubilant Hollisterstier Llc	1997-01-03	Not applicable			

NAME	DOSAGE	STRENGTH	ROUTE	LABELLER	MARKETING START	MARKETING END	
Mite, D. Farinae			Subcutaneous				
Allergenic Extracts - Standardized Mite Dermatophagoides Farinae	Liquid	30000 unit	Intradermal; Subcutaneous	Greer Laboratories	Not applicable	Not applicable	Canada
Allergenic Extracts Standardized Mite	Concentrate	30000 [AU]/1mL	Intradermal; Subcutaneous	Greer Laboratories	2010-02-03	Not applicable	USA
Allergenic Extracts Standardized Mite	Concentrate	10000 [AU]/1mL	Intradermal; Percutaneous; Subcutaneous	Greer Laboratories	2010-02-03	Not applicable	USA

Showing 1 to 10 of 25 entries

1 2 3 2

Mixture Products

Show 10 entries

Search

NAME	INGREDIENTS	DOSAGE	ROUTE	LABELLER	MARKETING START	MARKETING END	
Acarizax	Dermatophagoides farinae (6 unit) + Dermatophagoides pteronyssinus (6 unit)	Tablet	Sublingual	Alk Abello A/S	2017-11-06	Not applicable	Canada
Allergen Pack Dermatophagoides Farinae	Dermatophagoides farinae (15000 [AU]/1mL) + Sodium chloride (0.9 g/1mL)	Kit	Intradermal; Subcutaneous	Alvix Laboratories	2015-07-21	2018-03-08	USA
Allergenic Extract - Standardized Mite Mix	Dermatophagoides farinae (5000 unit) + Dermatophagoides pteronyssinus (5000 unit)	Liquid	Intradermal; Subcutaneous	Greer Laboratories	2002-08-20	Not applicable	Canada
Allergenic Extract Mixture Of Standardized Mites (15,000 Au/ml)	Dermatophagoides farinae (15000 unit) + Dermatophagoides pteronyssinus (15000 unit)	Solution	Percutaneous; Subcutaneous	Jubilant Hollisterstier Llc	1998-01-16	Not applicable	Canada
Allergenic Extract Mixture Of Standardized Mites (5,000 Au/ml)	Dermatophagoides farinae (5000 unit) + Dermatophagoides pteronyssinus (5000 unit)	Solution	Percutaneous; Subcutaneous	Jubilant Hollisterstier Llc	1998-01-16	Not applicable	Canada
Allergenic Extract Standardized Mite Mix	Dermatophagoides farinae (5000 unit) + Dermatophagoides pteronyssinus (5000 unit)	Liquid	Subcutaneous	Hollister Stier, Unit Pharm, Division Of Miles Canada Inc.	1992-12-31	1998-09-25	Canada
Allergenic Extract Standardized Mite Mix	Dermatophagoides farinae (15000 unit) + Dermatophagoides pteronyssinus (15000 unit)	Liquid	Subcutaneous	Hollister Stier, Unit Pharm, Division Of Miles Canada Inc.	1992-12-31	1998-09-23	Canada

NAME	INGREDIENTS	DOSAGE	ROUTE	LABELLER	MARKETING START	MARKETING END	
	Dermatophagoides farinae (5000 unit)						
Allergenic Extracts Standardized Mite	Dermatophagoides farinae (5000 [AU]/1mL) + Dermatophagoides pteronyssinus (5000 [AU]/1mL)	Concentrate	Intradermal; Percutaneous; Subcutaneous	Greer Laboratories	2010-02-03	Not applicable	
Allergenic Extracts Standardized Mite	Dermatophagoides farinae (15000 [AU]/1mL) + Dermatophagoides pteronyssinus (15000 [AU]/1mL)	Concentrate	Intradermal; Subcutaneous	Greer Laboratories	2010-02-03	Not applicable	

Showing 1 to 10 of 114 entries

[1](#)
[2](#)
[3](#)
[4](#)
[5](#)
[...](#)
[12](#)

Categories[Allergenic Extracts](#)[Cell-mediated Immunity](#)[Increased IgG Production](#)[Allergens](#)[Increased Histamine Release](#)[Standardized Insect Allergenic Extract](#)**UNII**[PR9U2YPF3Q](#)**CAS number**

Not Available

PHARMACOLOGY**Indication**

Dermatophagoides farinae extract is an allergen extract indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoidesfarinae house dust mites, or skin testing to licensed house dust mite allergen extracts. ODACTRA is approved for use in adults 18 through 65 years of age

Associated Conditions[House Dust Mite Allergy](#)**Pharmacodynamics**

Treatment with ACTAIR has been shown to induce a systemic antibody response towards house dust mite allergens, with an increase in specific IgG4 antibodies in some patients. These immunoglobulins may compete with IgE for allergen binding, thereby decreasing allergen capture and presentation.

Mechanism of action

The complete mechanisms of allergen immunotherapy are not clear and remain the subject of investigation. The allergic reaction is dependent on the presence of allergen-specific immunoglobulin E (IgE) antibodies that are bound to specific receptors on mast cells and basophils. The presence of IgE antibodies sensitizes these cells, and upon interaction with the appropriate allergens, histamine and other mediators are released which produce local or systemic responses in sensitive individuals, and characteristic symptoms of atopic diseases, such as allergic rhinitis and allergic asthma. Changes in serum antibody and T-lymphocyte responses resulting from immunotherapy have been demonstrated, and these changes often correlate closely with clinical (symptom) improvements. Specific mechanisms may vary depending on the nature of the allergic disease, the allergenic specificities of patients and populations, extract formulations, route of administration, dose and duration of treatment. Subcutaneous administration of allergenic extracts is known to elicit numerous immunological changes that are both time and dose-dependent. Many of these changes appear to be related to (or a precursor to) improvements in symptoms and other clinical parameters, as noted above. Specific changes found after immunotherapy with dust mite extracts include significant increases in mite-specific IgG4 antibodies, interleukin-10-positive T cells, and several T-cell receptors, and significant decreases in serum nitric oxide, eosinophil cationic protein, interleukin-4-positive T cells and IgE-mediated basophil histamine release.

Absorption

Allergens in ACTAIR consist mainly of proteins and glycoproteins. There is no direct bioavailability of intact allergens in the blood. Therefore, no pharmacokinetic studies in animals or in humans

Drugs

**Volume of distribution**

Not Available

**Protein binding**

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs ⓘ

Not Available

INTERACTIONS

Drug Interactions

Not Available

**Food Interactions**

Not Available

REFERENCES

General References

1. Liu L, Guo D, Liang Q, Ding S, Wu B, Zhang L, Li Q: The efficacy of sublingual immunotherapy with Dermatophagoides farinae vaccine in a murine atopic dermatitis model. Clin Exp Allergy. 2015 Apr;45(4):815-22. doi: 10.1111/cea.12417. [[PubMed:25258013](#)]
2. Eremina OIu, Stepanova GN: [The mechanism of action of permethrin on house dust mites]. Izv Akad Nauk Ser Biol. 1995 Jan-Feb;(1):72-9. [[PubMed:7894317](#)]
3. Mauro M, Boni E, Makri E, Incorvaia C: Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma. Expert Opin Drug Metab Toxicol. 2015;11(12):1937-43. doi: 10.1517/17425255.2015.1113255. Epub 2015 Nov 13. [[PubMed:26565665](#)]
4. Drug information [[Link](#)]

External Links

PubChem Substance

[347910575](#)

Wikipedia

[Dermatophagoides farinae](#)**ATC Codes**[V01AA03 – House dust mites](#)

- [V01AA – Allergen extracts](#)
- [V01A – ALLERGENS](#)
- [V01 – ALLERGENS](#)
- [V – VARIOUS](#)

AHFS Codes

92:05.00* – Allergenic Extracts

CLINICAL TRIALS

Clinical Trials ⓘ

Show

10

entries

Search

PHASE	STATUS	PURPOSE	CONDITIONS	COUNT
0	Recruiting	Basic	Asthma Bronchial	1

Drugs

3	Invitation Recruiting	Treatment	Allergic Asthma Due to Dermatophagoides Farinae / Allergic Asthma Due to Dermatophagoides Pteronyssinus / Allergic Rhinitis Due to House Dust Mite	1
---	--------------------------	-----------	--	---

Showing 1 to 3 of 3 entries

1 2



PHARMACOECONOMICS

Manufacturers Not Available

Packagers Not Available

Dosage forms Show entries

FORM	ROUTE	STRENGTH
Tablet	Sublingual	
Kit	Intradermal; Subcutaneous	
Liquid	Intradermal; Subcutaneous	5000 unit
Solution	Percutaneous; Subcutaneous	
Liquid	Subcutaneous	10000 unit
Liquid	Subcutaneous	30000 unit
Solution	Percutaneous; Subcutaneous	10000 unit
Solution	Percutaneous; Subcutaneous	30000 unit
Liquid	Subcutaneous	
Liquid	Intradermal; Percutaneous; Subcutaneous	10000 unit

Showing 1 to 10 of 33 entries

1 2 3 4

Prices Not Available

Patents Not Available

PROPERTIES

State Not Available

Experimental Properties Not Available

TAXONOMY

Classification Not classified

Drug created on December 01, 2015 13:03 / Updated on April 13, 2019 01:48

About

- [About DrugBank](#)
- [DrugBank Blog](#)
- [Wishart Research Group](#)
- [Terms of Use](#)
- [Privacy Policy](#)

Support

- [FAQ](#)
- [Help](#)
- [Email Support](#)



Commercial Products

[API Pricing](#)

This project is supported by the [Canadian Institutes of Health Research](#) (award #111062), [Alberta Innovates - Health Solutions](#), and by [The Metabolomics Innovation Centre \(TMIC\)](#), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by [Genome Alberta](#), [Genome British Columbia](#), and [Genome Canada](#), a not-for-profit organization that is leading Canada's

Drugs

